

**Consolidated Financial Results for the Third Quarter of FY2017**

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2016 Q3		FY2017 Q3		YoY
	Apr. 2016-Dec. 2016		Apr. 2017-Dec. 2017		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	37,475	100.0%	38,713	100.0%	103.3%
Cost of Sales	23,069	61.6%	23,351	60.3%	101.2%
Gross Profit	14,405	38.4%	15,362	39.7%	106.6%
Selling, General and Administrative Expenses	12,426	33.2%	11,902	30.7%	95.8%
Operating Income	1,975	5.3%	3,460	8.9%	175.2%
Profit Attributable to Owners of Parent	3,910	10.4%	3,026	7.8%	77.4%

**Forecast of Consolidated Financial Results for the FY2017**

	FY2016 Actual		FY2017 Forecast	
	Apr. 2016-Mar. 2017		Apr. 2017-Mar. 2018	
	Millions of Yen	Ratio	Millions of Yen	Ratio
Net Sales	37,475	100.0%	50,000	100.0%
Operating Income	1,975	5.3%	3,000	6.0%
Profit Attributable to Owners of Parent	3,910	10.4%	2,600	5.2%

**Sales of Main Products**

(Billions of yen)

Therapeutic Category	Products	FY2016 Q3 Actual	FY2017 Q3 Actual	FY2017 Forecast
Antihypertensive agent	CANDESARTAN*	9.86	10.45	13.55
Thyroid hormone	THYRADIN	4.19	4.13	5.40
Hyperlipidemic agent	LIPDIL	3.39	3.42	4.39
LH-RH derivative	LEUPRORELIN	2.96	3.23	4.11
Antihypertensive agent	AMLODIPINE	1.30	1.26	1.64
Poorly absorbable antimicrobial agent	RIFXIMA	0.07	0.71	1.45

\*Including CANDESARTAN formulation's sales